• Free shipping from $200
  • collecting affordable offers from best manufacturers worldwide
  • Special offers every week
Your cart

Eyegate Pharmaceuticals To Present At The 17th Annual Rodman And Renshaw Global Investment Conference

July 3, 2023

WALTHAM, Mass., Sept. 1, 2015 — Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced Stephen From, President & Chief Executive Officer of EyeGate is scheduled to present at the 17th Annual Rodman & Renshaw Global Investment conference being held September 8-10, 2015 in New York, NY.

Details of the presentations are as follows:

Conference: Rodman & Renshaw Global Investment Conference
Date: Wednesday, September 9th, 2015
Time: 5.30 p.m. EDT
Room: Library, 2nd Floor of the St. Regis Hotel, NYC

Investors attending the conferences who would like to schedule a 1-on-1 meeting with EyeGate’s management may do so by contacting their Rodman & Renshaw representatives, or Joseph Green of The Ruth Group at jgreen@theruthgroup.com.

About EyeGate:

EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP-437, the Company’s first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate® II Delivery System. For more information, please visit www.EyeGatePharma.com.

Safe Harbor Statement:

Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will,” or words of similar meaning and include, but are not limited to, statements regarding the outlook for our future business and financial performance. Forward-looking statements are based on our current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially from those in the forward-looking statements due to global political, economic, business, competitive, market, regulatory and other factors and risks, including, among other things, certain risk factors described under the heading “Risk Factors” contained in our Annual Report on Form 10-K filed with the SEC on March 31, 2015, or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Lee Roth / Joseph Green The Ruth Group for Eyegate Pharmaceuticals 646-536-7012 / 7013